News

Video

Industry Outlook 2025: Political Implications for Pharma

Pharmaceutical Technology® spoke with Alexander Seyf, CEO and co-founder of Autolomous, about how the political landscape may impact the pharmaceutical industry.

The fundamentals of healthcare are established and supported in the United States, Alexander Seyf, CEO and co-founder of Autolomous, says, and while the changing political landscape might come with some bumps in the road, he believes the mission to treat patients will continue forward.

“I hope that [politicians realize] they can be one of the customers of the pharma and biotech,” Seyf says. “So, I would say at the core of it, we all are human, and sometimes we need to have a little bit of selfish kind of motivation to do the right thing. So, either we going to see a lot of people who have a higher ground, and they will push the support [of] pharma and biotech forward, or they might have a selfish kind of objective at the end, [which] will yield to a positive result. So, I'm pretty positive, because I believe you can change people, but the system will take longer than four years to change.”

Click the video above to watch the full interview.

About the speaker

Alexander Seyf is CEO and Co-Founder of Autolomous.

Newsletter

Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.

Related Videos
A global supply chain map, visualizing the complex network of transportation routes and distribution centers | Image Credit: © venusvi - stock.adobe.com
Shortcut from point A to point B | Image Credit: © Olivier Le Moal - stock.adobe.com
Behind the Headlines, Episode 21: Waters-BD Merger, Merck’s $10B Bet, and Biotech’s Investment Frontiers
Wooden blocks spelling TARIFFS are placed on a map of North America, specifically over the United States and Mexico | Image Credit: © Rokas - stock.adobe.com
Jason Waite, International Trade Expert, Alston & Bird
Simona Guidi, Associate Director, ProPharma
Tore Bergsteiner
Behind the Headlines, Episode 20: CAR-T Milestones, Abbvie and Eli Lilly M&A Moves, and More
Related Content